ARBUTUS BIOPHARMA CORP (ABUS) Fundamental Analysis & Valuation

NASDAQ:ABUS • CA03879J1003

Current stock price

4.48 USD
-0.04 (-0.88%)
At close:
4.4898 USD
+0.01 (+0.22%)
After Hours:

This ABUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ABUS Profitability Analysis

1.1 Basic Checks

  • In the past year ABUS has reported negative net income.
  • ABUS had a negative operating cash flow in the past year.
  • ABUS had negative earnings in each of the past 5 years.
  • In the past 5 years ABUS always reported negative operating cash flow.
ABUS Yearly Net Income VS EBIT VS OCF VS FCFABUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -35.41%, ABUS is in the better half of the industry, outperforming 60.73% of the companies in the same industry.
  • ABUS has a Return On Equity of -43.75%. This is in the better half of the industry: ABUS outperforms 67.31% of its industry peers.
Industry RankSector Rank
ROA -35.41%
ROE -43.75%
ROIC N/A
ROA(3y)-46.31%
ROA(5y)-43.54%
ROE(3y)-61.42%
ROE(5y)-57.44%
ROIC(3y)N/A
ROIC(5y)N/A
ABUS Yearly ROA, ROE, ROICABUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ABUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABUS Yearly Profit, Operating, Gross MarginsABUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ABUS Health Analysis

2.1 Basic Checks

  • ABUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ABUS has more shares outstanding than it did 1 year ago.
  • ABUS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ABUS has been reduced compared to a year ago.
ABUS Yearly Shares OutstandingABUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ABUS Yearly Total Debt VS Total AssetsABUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • ABUS has an Altman-Z score of 8.62. This indicates that ABUS is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 8.62, ABUS is in the better half of the industry, outperforming 79.88% of the companies in the same industry.
  • ABUS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • ABUS has a Debt to Equity ratio (0.04) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 8.62
ROIC/WACCN/A
WACC9.2%
ABUS Yearly LT Debt VS Equity VS FCFABUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 15.73 indicates that ABUS has no problem at all paying its short term obligations.
  • The Current ratio of ABUS (15.73) is better than 93.04% of its industry peers.
  • ABUS has a Quick Ratio of 15.73. This indicates that ABUS is financially healthy and has no problem in meeting its short term obligations.
  • ABUS has a Quick ratio of 15.73. This is amongst the best in the industry. ABUS outperforms 93.04% of its industry peers.
Industry RankSector Rank
Current Ratio 15.73
Quick Ratio 15.73
ABUS Yearly Current Assets VS Current LiabilitesABUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ABUS Growth Analysis

3.1 Past

  • ABUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.35%, which is quite impressive.
  • Looking at the last year, ABUS shows a very strong growth in Revenue. The Revenue has grown by 128.21%.
  • Measured over the past years, ABUS shows a quite strong growth in Revenue. The Revenue has been growing by 15.30% on average per year.
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.43%
Revenue 1Y (TTM)128.21%
Revenue growth 3Y-28.8%
Revenue growth 5Y15.3%
Sales Q2Q%-33.23%

3.2 Future

  • ABUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.78% yearly.
  • ABUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 88.88% yearly.
EPS Next Y9.33%
EPS Next 2Y31.02%
EPS Next 3Y6.51%
EPS Next 5Y40.78%
Revenue Next Year-92.66%
Revenue Next 2Y-19.5%
Revenue Next 3Y60.1%
Revenue Next 5Y88.88%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABUS Yearly Revenue VS EstimatesABUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
ABUS Yearly EPS VS EstimatesABUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABUS Valuation Analysis

4.1 Price/Earnings Ratio

  • ABUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ABUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABUS Price Earnings VS Forward Price EarningsABUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABUS Per share dataABUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.02%
EPS Next 3Y6.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABUS Dividend Analysis

5.1 Amount

  • No dividends for ABUS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABUS Fundamentals: All Metrics, Ratios and Statistics

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (4/2/2026, 8:06:45 PM)

After market: 4.4898 +0.01 (+0.22%)

4.48

-0.04 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23
Earnings (Next)04-30
Inst Owners64.57%
Inst Owner Change1.77%
Ins Owners0.84%
Ins Owner Change0.23%
Market Cap861.59M
Revenue(TTM)14.08M
Net Income(TTM)-33.50M
Analysts84.44
Price Target5.78 (29.02%)
Short Float %10.92%
Short Ratio6.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.74%
Min EPS beat(2)-26.5%
Max EPS beat(2)43.98%
EPS beat(4)2
Avg EPS beat(4)28.71%
Min EPS beat(4)-26.5%
Max EPS beat(4)120.64%
EPS beat(8)5
Avg EPS beat(8)16.91%
EPS beat(12)8
Avg EPS beat(12)14.39%
EPS beat(16)11
Avg EPS beat(16)14.53%
Revenue beat(2)1
Avg Revenue beat(2)-5.93%
Min Revenue beat(2)-59.06%
Max Revenue beat(2)47.2%
Revenue beat(4)2
Avg Revenue beat(4)136.85%
Min Revenue beat(4)-59.06%
Max Revenue beat(4)562.08%
Revenue beat(8)2
Avg Revenue beat(8)58.55%
Revenue beat(12)3
Avg Revenue beat(12)32.57%
Revenue beat(16)5
Avg Revenue beat(16)40.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.18
P/FCF N/A
P/OCF N/A
P/B 11.25
P/tB 11.25
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.07
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.41%
ROE -43.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.31%
ROA(5y)-43.54%
ROE(3y)-61.42%
ROE(5y)-57.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.73
Quick Ratio 15.73
Altman-Z 8.62
F-Score5
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)28.33%
Cap/Depr(5y)33.39%
Cap/Sales(3y)2.84%
Cap/Sales(5y)3.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.43%
EPS Next Y9.33%
EPS Next 2Y31.02%
EPS Next 3Y6.51%
EPS Next 5Y40.78%
Revenue 1Y (TTM)128.21%
Revenue growth 3Y-28.8%
Revenue growth 5Y15.3%
Sales Q2Q%-33.23%
Revenue Next Year-92.66%
Revenue Next 2Y-19.5%
Revenue Next 3Y60.1%
Revenue Next 5Y88.88%
EBIT growth 1Y65.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.88%
OCF growth 3YN/A
OCF growth 5YN/A

ARBUTUS BIOPHARMA CORP / ABUS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ARBUTUS BIOPHARMA CORP (ABUS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ABUS.


What is the valuation status for ABUS stock?

ChartMill assigns a valuation rating of 0 / 10 to ARBUTUS BIOPHARMA CORP (ABUS). This can be considered as Overvalued.


What is the profitability of ABUS stock?

ARBUTUS BIOPHARMA CORP (ABUS) has a profitability rating of 1 / 10.